Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
GMAB Genmab
- 21.300
- +0.380+1.82%
Close Feb 14 16:00 ET
- 21.190
- -0.110-0.52%
Post 19:29 ET
13.53BMarket Cap12.48P/E (TTM)
21.310High21.005Low2.42MVolume21.080Open20.920Pre Close51.35MTurnover0.39%Turnover Ratio12.48P/E (Static)635.40MShares31.88052wk High2.62P/B13.39BFloat Cap18.63552wk Low--Dividend TTM628.61MShs Float49.070Historical High--Div YieldTTM1.46%Amplitude16.240Historical Low21.238Avg Price1Lot Size
About Genmab Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGMAB
Company NameGenmab
Listing DateJul 18, 2019
Issue Price17.75
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees2682
Securities TypeDR
ADS Ratio10.0 : 1.0
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 54.80M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 13.20M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 24.00M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 11.00M
- Dr. Judith Klimovsky, M.D.
- Executive Vice President and Chief Development Officer
- 27.90M
- Rayne Waller
- Executive Vice President and Chief Technical Operations Officer
- 7.30M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 16.60M
- Brad Bailey
- Executive Vice President and Chief Commercial Officer
- 11.10M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 25.80M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.60M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.60M
- Deirdre P. Connelly
- Chairman of the Board
- 3.30M
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 2.10M
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 1.40M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 1.40M
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 2.00M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.90M
- Elizabeth G. O’Farrell
- Independent Director
- 2.60M
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.